Zacks Investment Research upgraded shares of Relmada Therapeutics Inc (NASDAQ:RLMDD) from a hold rating to a buy rating in a research report released on Wednesday morning. They currently have $5.25 price objective on the stock.

According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York. “

TRADEMARK VIOLATION WARNING: “Relmada Therapeutics Inc (RLMDD) Upgraded to Buy at Zacks Investment Research” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this story can be read at

5 Day Chart for NASDAQ:RLMDD

Receive News & Stock Ratings for Relmada Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics Inc and related stocks with our FREE daily email newsletter.